With a history spanning more than two decades, XVIVO’s journey began in 1998 when founder Dr. Magnus Nilsson acquired the rights to PERFADEX®, the gold standard in lung transplant preservation. Since then, XVIVO has been at the forefront of medical advancements in transplantation medicine, equipping leading clinicians and researchers to push the boundaries of their field.
Acquisition of Avionord Machines & Perfusion, our former Italian distributor.
Kidney Assist Transport (2nd gen) CE marked and FDA 510(k) cleared.
Acquisition of Star Teams. An organ recovery company serving the U.S. market.
Acquisition of Organ Assist XVIVO becomes the first all organ company.
PERFADEX® Plus. FDA 510(k) cleared and CE marked.
First heart transplant using a preservation technique developed by XVIVO partner Prof. Stig Steen.
Kidney Assist CE marked.
XPS™ approved by FDA under HDE in the US. CE marked on the EU market.
Kidney Assist Transport (1st gen) / Liver Assist CE marked
STEEN Solution™ CE marked.
PERFADEX® FDA 510(k) cleared.
The first EVLP lung transplant performed with STEEN Solution™.
Organ Assist founded by Arjan van der Plaats and Professor Gerard Rakhorst
XVIVO Perfusion founded and research collaboration initiated with Prof. Stig Steen.